epratuzumab

Home
Ligands
epratuzumab

GtoPdb Ligand ID: 8088

Compound class: Antibody

Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions [1].
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 [5].

No information available.

No information available.

Summary of Clinical Use
Epratuzumab is an investigational immunotherapy in Phase 3 clinical trial for the treatment of systemic lupus erythematosus (SLE; failure to show efficacy reported in [3]) [8], relapsed acute lymphoblastic leukemia (ALL) and relapsed/refractory, aggressive non-Hodgkin's lymphoma (NHL). Click here to link to ClinicalTrials.gov's full listing of registered epratuzumab trials.

Summary of Clinical Use

Epratuzumab is an investigational immunotherapy in Phase 3 clinical trial for the treatment of systemic lupus erythematosus (SLE; failure to show efficacy reported in [3]) [8], relapsed acute lymphoblastic leukemia (ALL) and relapsed/refractory, aggressive non-Hodgkin's lymphoma (NHL). Click here to link to ClinicalTrials.gov's full listing of registered epratuzumab trials.

Mechanism Of Action and Pharmacodynamic Effects
Epratuzumab binds to the CD22 glycoprotein on the surface of mature and malignant B-cells and appears to stimulate antibody-dependent cellular cytotoxicity (ADCC) as its main anti-tumour mechanism [2,4].

Mechanism Of Action and Pharmacodynamic Effects

Epratuzumab binds to the CD22 glycoprotein on the surface of mature and malignant B-cells and appears to stimulate antibody-dependent cellular cytotoxicity (ADCC) as its main anti-tumour mechanism [2,4].